These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28121355)

  • 1. Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.
    Zhu BP; Guo ZQ; Lin L; Liu Q
    Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):61-67. PubMed ID: 28121355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer.
    Wang Y; Zhang XF; Dai J; Zheng YC; Zhang MG; He JJ
    J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):559-562. PubMed ID: 23904377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
    Lucarelli G; Rutigliano M; Bettocchi C; Palazzo S; Vavallo A; Galleggiante V; Trabucco S; Di Clemente D; Selvaggi FP; Battaglia M; Ditonno P
    J Urol; 2013 Dec; 190(6):2271-7. PubMed ID: 23665271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
    Smith MR; Saad F; Oudard S; Shore N; Fizazi K; Sieber P; Tombal B; Damiao R; Marx G; Miller K; Van Veldhuizen P; Morote J; Ye Z; Dansey R; Goessl C
    J Clin Oncol; 2013 Oct; 31(30):3800-6. PubMed ID: 24043751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer.
    He JJ; Zhi K; Liu GF
    Onkologie; 2011; 34(11):584-8. PubMed ID: 22104154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy.
    Perlmutter MA; Lepor H
    Urology; 2008 Mar; 71(3):501-5. PubMed ID: 18342197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
    Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
    Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Combined Detection of Serum PSA, PCA3, and Apparent Diffusion Coefficient of Magnetic Resonance Imaging in Bone Metastasis of Prostate Cancer.
    Xu F; Liu L; Yan S; Wang Q; Shi S
    Altern Ther Health Med; 2024 Oct; 30(10):516-521. PubMed ID: 38401099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
    Wolff JM; Bares R; Jung PK; Buell U; Jakse G
    Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.
    Carlinfante G; Vassiliou D; Svensson O; Wendel M; Heinegård D; Andersson G
    Clin Exp Metastasis; 2003; 20(5):437-44. PubMed ID: 14524533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal measure of PSA kinetics to identify prostate cancer.
    Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M
    Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.